| Literature DB >> 30373235 |
Umeorah Ernest1, Hai-Yan Chen2, Ming-Jun Xu3, Yasamin Davatgaran Taghipour4, Muhammad Hassham Hassan Bin Asad5, Roja Rahimi6, Ghulam Murtaza7.
Abstract
Recent evidence has extensively demonstrated the anticancer potential of nutraceuticals, including plant polyphenols. Polymeric nanocarrier systems have played an important role in improving the physicochemical and pharmacological properties of polyphenols, thus ameliorating their therapeutic effectiveness. This article summarizes the benefits and shortcomings of various polymeric systems developed for the delivery of polyphenols in cancer therapy and reveals some ideas for future work.Entities:
Keywords: cancer therapeutics; cell lines; nanoparticles; polymeric carriers; polyphenols
Mesh:
Substances:
Year: 2018 PMID: 30373235 PMCID: PMC6278361 DOI: 10.3390/molecules23112787
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Polyphenol-loaded polymersomes for the treatment of cancer.
| No. | Components of Nanoparticles | Method of Preparation | Polyphenol + Synergistic Agent | Type of Cancer In Vitro Model/In Vivo Model Promisingly Ttreated with the Fabricated Nanotherapeutic Formulation | References |
|---|---|---|---|---|---|
| 1 | Polyvinyl pyrrolidone–PEG | Emulsion evaporation | Plant polyphenols | Glioblastoma DBTRG-05MG | [ |
| 2 | Keratin | Solvent evaporation | Curcumin | Cervical cancer HeLa | [ |
| 3 | Gelatin | Solvent evaporation | Curcumin | Lung cancer H1299 | [ |
| 4 | PEG–Oleic acid | Thin layer evaporation | Curcumin | Brain cancer U87MG | [ |
PEG: polyethylene glycol.
Polyphenol-loaded polymeric micelles for the treatment of cancer.
| No. | Components of Nanoparticles | Method of Preparation | Polyphenol + Synergistic Agent | Type of Cancer In Vitro Model/In Vivo Model Promisingly Treated with the Fabricated Nanotherapeutic Formulation | References |
|---|---|---|---|---|---|
| 1 | Gelatin–Dextran | Self-assembly-Genipin-Crosslinking | Plant polyphenols | Breast cancer MCF-7 | [ |
| 2 | Gelatin–Dextran | Self-assembly-Genipin-Crosslinking | Curcumin | Cervical cancer HeLa Healthy mice | [ |
| 3 | Casein | Self-assembly | Curcumin | Cervical cancer HeLa | [ |
| 4 | Zein–PEG | Self-assembly | Curcumin | Ovarian cancer NCI Healthy mice | [ |
| 5 | Chitosan–Stearic acid | Self-assembly | Curcumin | Colon cancer Primary Xenograft mice | [ |
| 6 | PEG–Polyanhydride esters | Solvent evaporation | Curcumin | Cervical cancer HeLa | [ |
| 7 | PEG–Polylactic acid | Solvent evaporation | Curcumin + Doxorubicin | Breast cancer MCF-7 Xenograft mice | [ |
| 8 | PEG–Polycaprolactone | Thin-layer evaporation | Curcumin | Ovarian cancer A2780t | [ |
| 9 | PEG–Polycaprolactone | Thin-layer evaporation | Curcumin | Breast cancer MDA-MB-436 | [ |
| 10 | PEG–Polycaprolactone | Self-assembly | Curcumin | Breast cancer 4T1–4T1 Xenograft mice | [ |
| 11 | PEG–Polycaprolactone | Thin-layer evaporation | Curcumin | Cervical cancer HeLa Xenograft mice | [ |
| 12 | PEG–Polycaprolactone | Thin-layer evaporation | Curcumin | Colon HT-29 | [ |
| 13 | PEG–Polycaprolactone | Thin-layer evaporation | Curcumin + Doxorubicin | Lung cancer LL/2 Xenograft mice | [ |
| 14 | Linoleic acid-PEG-Polycaprolactone | Self-assembly | Curcumin | Cervical cancer HeLa Healthy mice | [ |
| 15 | Linoleic acid-PEG-Polycaprolactone | Self-assembly | Curcumin | Lung A549 | [ |
| 16 | PEG -Palmitic acid | Self-assembly | Curcumin | Cervical cancer HeLa | [ |
| 17 | PEG2000-DSPE | Thin-layer evaporation | Curcumin + Paclitaxel | Ovarian cancer SK-OV-3TR | [ |
| 18 | PEG2000-DSPE | Thin-layer evaporation | Curcumin + Paclitaxel | Ovarian cancer NCI SK-OV-3TR Xenograft mice | [ |
| 19 | PEG2000-DSPE | Thin-layer evaporation | Curcumin + Doxorubicin | Colon cancer HCT-116 Xenograft mice | [ |
| 20 | PEG- Doxorubicin | Self-assembly | Curcumin + Doxorubicin | Cervical cancer HeLa HepG2 Xenograft mice | [ |
| 21 | PEG-Doxorubicin | Self-assembly | Curcumin + Doxorubicin | Hepatic HepG2 | [ |
| 22 | Poloxamers F127 F68 | Thin-layer evaporation | Curcumin | Cervical cancer HeLa | [ |
| 23 | Poloxamers-PEG-Succinate | Solvent evaporation | Curcumin | Ovarian cancer NCI | [ |
| 24 | Poloxamers F127 | Thin-layer evaporation | Resveratrol, Curcumin + Doxorubicin | Ovarian cancer SKOV-3 Healthy mice | [ |
| 25 | Poloxamers F127 | Thin-layer evaporation | Resveratrol, Quercetin + Doxorubicin | Ovarian cancer SKOV-3 Healthy mice | [ |
| 26 | Apolipoprotein-E3 | recombinant DNA | Resveratrol | Glioblastoma A-172 | [ |
| 27 | Polycaprolactone-PEG-Succinate | Thin-layer evaporation | Resveratrol | Breast cancer MCF-7 | [ |
| 28 | Casein | Self-assembly | Epigallocatechin gallate | Colon cancer HT-29 | [ |
| 29 | Polylactic acid-PEG | Thin-layer evaporation | Epigallocatechin gallate | Pancreatic cancer MiaPaca-2 | [ |
Note: PEG2000-DSPE—1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxypolyethylene glycol-2000].
Polyphenol-loaded polymeric nanoparticles for the treatment of cancer in vitro.
| No. | Components of Nanoparticles | Method of Preparation | Polyphenol + Synergistic Agent | Type of Cancer In Vitro Model In Vivo Model Promisingly Treated with the Fabricated Nanotherapeutic Formulation | References |
|---|---|---|---|---|---|
| 1 | Polylactic-co-glycolic acid PLGA–PEG | Emulsion solvent evaporation | Pomgranade polyphenols | Breast cancer MCF-7, Hs578T | [ |
| 2 | Chitosan | Ionic gelation | Tea polyphenols | Hepatic cancer Hep G2 | [ |
| 3 | Polycaprolactone | EXP | Plant polyphenols | Gastric cancer MNK28 | [ |
| 4 | Alginate–Chitosan–Poloxamers F127 | Ionic gelation | Curcumin | Cervical cancer HeLa | [ |
| 5 | Fibrinogen | CaCl2 Crosslinking | Curcumin | Prostate cancer PC3 | [ |
| 6 | PLGA | Emulsion solvent evaporation | Curcumin | Breast cancer MCF-7 | [ |
| 7 | PLGA | Emulsion solvent evaporation | Curcumin | Osteosarcoma U2OS | [ |
| 8 | Chitin | Emulsion solvent evaporation | Curcumin | Melanoma A375 | [ |
| 9 | Peptide | Ionic gelation | Curcumin | Medulloblastoma DAOY | [ |
| 10 | Self-assembly | Curcumin | Pancreatic cancer Capan-1, MiaPaCa2, PL-5, PL-8, Su86.86, BxPC-3, PANC-1, E3LZ10.7 Healthy mice | [ | |
| 11 | PLGA–PEG | Nanoprecipitation | Curcumin | Colon cancer HT-29 Healthy mice | [ |
| 12 | PLGA | Nanoprecipitation | Curcumin | Ovarian cancer A2780, A2780CP | [ |
| 13 | Cellulose | Nanoprecipitation | Curcumin | Prostate cancer C4-2, PC-3, LNCaP, DU-145 | [ |
| 14 | PLGA | Nanoprecipitation | Curcumin | Prostate cancer DU-145, PC-3 Xenograft mice | [ |
| 15 | Human serum albumin | Emulsion solvent evaporation | Curcumin | Colon cancer HCT116 HCT116 Xenograft mice | [ |
| 16 | Human serum albumin | Emulsion solvent evaporation | Curcumin | Pancreatic cancer MiaPaCa2 | [ |
| 17 | Gelatin–Polyacryl-amidoglycolic acid | Emulsion polymerization | Curcumin | Colon cancer HCT-116 | [ |
| 18 | Silk fibroin | Physical adsorption and coprecipitation | Curcumin | Human hepatocellular carcinoma Hep3B, human neuroblastoma Kelly cells, Human bone marrow-derived mesenchymal stem cells hBMSCs | [ |
| 19 | Chitosan–Polybutyl cyanoacrylate | Emulsion polymerization | Curcumin + Doxorubicin | Breast cancer MCF-7 | [ |
| 20 | PLGA | Emulsion solvent evaporation | Curcumin + 5-fluorouracil | Breast cancer MCF-7 | [ |
| 21 | PLGA | Nanoprecipitation | Curcumin + Cisplatin | Ovarian cancer A2780CP | [ |
| 22 | PLGA | Nanoprecipitation | Curcumin + Cisplatin | Breast cancer MDA-MB-231 | [ |
| 23 | Radical polymerization | Curcumin + Gemcitabine | Pancreatic cancer Pa03C Xenograft mice | [ |
Polyphenol-loaded polymeric nanoparticles for the treatment of cancer in vitro.
| No. | Components of Nanoparticles | Method of Preparation | Polyphenol + Synergistic Agent | Type of Cancer In Vitro Model In Vivo Model Promisingly Treated with the Fabricated Nanotherapeutic Formulation | References |
|---|---|---|---|---|---|
| 1 | Gelatin–Polyelectrolyte | Layer-by-layer | Epigallocatechin gallate | Breast cancer MBA-MD-231 | [ |
| 2 | PLGA–PEG | Nanoprecipitation | Epigallocatechin gallate | Prostate cancer LNCaP | [ |
| 3 | Casein-phospho-peptide–Chitosan | Genipin-Crosslinking | Epigallocatechin gallate | Hepatic cancer HepG2 | [ |
| 4 | Casein-phospho-peptide–Chitosan | Genipin-Crosslinking | Epigallocatechin gallate | Gastric cancer BGC823 | [ |
| 5 | Casein-phospho-peptide–Chitosan | Genipin-Crosslinking | Epigallocatechin gallate | Colon cancer Caco-2 | [ |
| 6 | Hyaluronic acid | Self-assembly | Epigallocatechin gallate + Doxorubicin | Cancer of the external auditory canal | [ |
| 8 | Chitosan | Ionic gelation | Epigallocatechin gallate | Prostate cancer 22R_1 Xenograft mice | [ |
| 7 | Chitosan | Ionic gelation | Epigallocatechin gallate | Melanoma Mel928 Mel928 Xenograft mice | [ |
| 9 | Chitosan–Gelatin–PEG | Ionic gelation | Epigallocatechin gallate | Gastric cancer Luc MKN45 Xenograft mice | [ |
| 10 | PLGA | Nanoprecipitation | Epigallocatechin gallate + Cisplatin | Lung cancer A549 | [ |
| 11 | PLGA | Nanoprecipitation | Epigallocatechin gallate + Cisplatin | Cervical cancer HeLA | [ |
| 12 | PLGA | Nanoprecipitation | Theaflavin | Leukemia THP-1 | [ |
| 13 | PLGA | Solvent evaporation | Epigallocatechin gallate + Cisplatin | Lung cancer A549 Ehrlich ascites carcinoma Xenograft mice | [ |
| 14 | PLGA | Solvent evaporation | Epigallocatechin gallate | Cervical cancer HeLA | [ |
| 15 | PLGA | Solvent evaporation | Theaflavin | Leukemia THP-1 | [ |
| 16 | PLGA | Solvent evaporation | Theaflavin | Cancer of the external auditory canal | [ |
| 17 | PLGA–PEG | Nanoprecipitation | Resveratrol | Prostate cancer DU-145, LNCaP | [ |
| 18 | Bovine serum albumin | Nanoprecipitation | Resveratrol | Lung cancer NCI-H460 | [ |
| 19 | Bovine serum albumin | Nanoprecipitation | Resveratrol | Ovarian cancer SKOV3 | [ |
| 20 | PLGA | Emulsion method | Resveratrol | Breast cancer MCF-7 | [ |
| 21 | Maleimide–PEG–Polylactic acid | Self-assembly | Resveratrol | Glioblastoma CT26, U87 CT26 Xenograft mice | [ |
| 22 | Chitosan | Ionic gelation | Quercetin + 5-fluorouracil | Pancreas cancer MiaPaCa2 | [ |
| 23 | PLGA | Emulsion solvent evaporation | Quercetin + Tamoxifen | Breast cancer MCF-7 Xenograft mice | [ |
| 24 | PLGA | Emulsion solvent evaporation | Quercetin + Tamoxifen | Colon cancer Caco2 | [ |
| 25 | Hyaluronic acid–Polybutyl cyanoacrylate–a-Tocopheryl–PEG–Succinate | Radical polymerization | Morin hydrate | Lung cancer A549 S180 Xenograft mice | [ |
| 26 | Hyaluronic acid–Polybutyl cyanoacrylate –Tocopheryl–PEG–Succinate | Radical polymerization | Morin hydrate | Hepatic cancer L02 | [ |
Polyphenol-loaded polymeric conjugates for the treatment of cancer.
| No. | Components of Nanoparticles | Method of Preparation | Polyphenol + Synergistic Agent | Type of Cancer In Vitro Model In Vivo Model Promisingly Treated with the Fabricated Nanotherapeutic Formulation | References |
|---|---|---|---|---|---|
| 1 | PEG | Condensation method | Curcumin | Glioma C6 | [ |
| 2 | PEG | Condensation method | Curcumin | Prostate cancer PC-3 | [ |
| 3 | PEG | Condensation method | Curcumin + Gemcitabine | Pancreatic cancer MiaPaCa2, PANC-1, BxPC-3, AsPC-1 | [ |
| 4 | PEG | Condensation method | Resveratrol + Bicalutamide | Cervical cancer HeLa | [ |
| 5 | PEG | Condensation method | Resveratrol + Bicalutamide | Breast cancer MCF-7 | [ |
| 6 | Carboxymethyl chitosan | Condensation method | Quercetin + Paclitaxel | Hepatic cancer HepG2 HepG2 Xenograft mice | [ |
| 7 | PEG | Condensation method | Curcumin | Cervical cancer HeLa, Breast cancer EMT6 EMT6 Xenograft mice | [ |
| 8 | PEG–Desaminotyrosyl-tyrosine ethyl ester | Condensation method | Curcumin | Breast cancer MDA-MB-231 | [ |
| 9 | PEG | Condensation method | Catechin + Bortezomib | Breast cancer MDA-MB-231 | [ |
| 10 | Hyaluronic acid–Polyethyleneimine | Condensation method | Epigallocatechin gallate + Granzyme B | Colon cancer HCT-116 | [ |
| 11 | Dextran | Free radical grafting | Catechin | Pancreatic cancer MiaPaca-2, PL45 | [ |
| 12 | Dextran | Free radical grafting | Catechin | Neuroblastoma IMR-32, IMR-32-CisRes, BE2-C Xenograft mice | [ |
| 13 | Dextran | Enzyme laccase catalysis | Catechin | Neuroblastoma IMR-32 | [ |
| 14 | Polymethacrylic acid | Free radical grafting | Quercetin | Cervical cancer HeLa | [ |
| 15 | Gelatin | Free radical grafting | Gallic acid | Prostate cancer DU-145, PC-3 | [ |
| 16 | Gelatin | Free radical grafting | Gallic acid | Renal cancer A498 | [ |
Figure 1A schematic representation showing the ameliorated effect of functionalization on the cytocompatibility of graphene and carbon nanotubes.
Polyphenol-loaded carbon-based nanohybrids for the treatment of cancer.
| No. | Components of Nanoparticles | Method of Preparation | Polyphenol + Synergistic Agent | Type of Cancer In Vitro Model/In Vivo Model Promisingly Treated with the Fabricated Nanotherapeutic Formulation | References |
|---|---|---|---|---|---|
| 1 | Graphene oxide | Reduction method | Tea polyphenols | Colon cancer HT29, SW48 | [ |
| 2 | Graphene oxide | Reduction method | Resveratrol | Ovarian cancer A2780 | [ |
| 3 | Polycapro-lactone–MWNT | Electrospinning | Tea polyphenols | Lung cancer A549 | [ |
| 4 | Polycapro-lactone–MWNT | Electrospinning | Tea polyphenols | Hepatic HepG2 | [ |
| 5 | Gelatin–MWNT | Coating | Catechin + Radiotherapy | Prostate cancer DY-145, PC-3, LNCap | [ |
| 6 | Gelatin–MWNT | Coating | Catechin | Cervical cancer HeLa | [ |
| 7 | Polymeth-acrylic acid–MWNT | Radical coupling | Quercetin | Cervical cancer HeLa | [ |
| 8 | Polymeth-acrylic acid–MWNT | Radical coupling | Quercetin + Cisplatin | Neuroblastoma IMR-32 | [ |
Note: MWNT—Multiple-walled carbon nanotubes.
Figure 2A concept figure showing drug release from magnetic nanoparticles under the effect of alternating magnetic field.
Polyphenol-loaded magnetic nanoparticles for the treatment of cancer.
| No. | Components of Nanoparticles | Method of Preparation | Polyphenol + Synergistic Agent | Type of Cancer In Vitro Model/In Vivo Model Promisingly Treated with the Fabricated Nanotherapeutic Formulation | References |
|---|---|---|---|---|---|
| 1 | Hyaluronic acid–Iron | Layer-by-layer | Curcumin | Colon cancer Caco-2 | [ |
| 2 | Polyvinyl pyrrolidone–Iron | Layer-by-layer | Curcumin | Glioma C6 | [ |
| 3 | Iron–Poloxamers F127 | Nanopre-cipitation | Curcumin | Pancreatic cancer HPAF-II, Panc-1/Xenograft mice | [ |
| Iron–Dextran | Solvation method | Catechin | Pancreatic cancer MIA Paca2 | [ | |
| 4 | Iron | Reduction process | Epigallocatechin gallate | Colon cancer CT-26/Xenograft mice | [ |
| 5 | Nickel | Electro-chemical deposition | Quercetin | Hepatic cancer SMMC-7721 | [ |